用ＨＡ（高三尖杉酯碱、阿糖胞苷）方案，治疗慢性髓细胞白血病（ＣＭＬ）慢性期６８例，完全缓解（ＣＲ）３６例，部分缓解（ＰＲ）２３例，ＣＲ率５２９％，总有效率８６８％。本方案具有降低白细胞和缩脾作用明显，停药易反复，严重骨髓抑制后易急变等特点。长期观察５４例ＣＭＬ的治疗效果，均数生存期３６８个月，分组随访观察表明，ＨＡ化疗组比单用马利兰和单用靛玉红组急变率、死亡率高，均数生存期较短。ＨＡ化疗不能控制或延缓急性变的发生 Using HA (Homoharringtonine, Cytarabine) regimen in the treatment of chronic myeloid leukemia (CML) in 68 patients with chronic phase, complete remission (CR) in 36 patients, partial remission (PR) in 23 patients, CR rate 52 9 %, with an overall efficiency of 86.8%. This program has the characteristics of reducing white blood cells and reducing the spleen, obviously stopping the drug, severe bone marrow suppression and rapid change. The long-term observation of the treatment effect of 54 cases of CML, the mean survival time of 36  8 months, group follow-up observations show that HA chemotherapy group than the use of Mallilan alone and Diaoyuhong group, the rate of emergency, high mortality, mean survival time short. HA chemotherapy does not control or delay the onset of acute changes